Hereditary/Acquired Bleeding Disorders

This editorial comments on a prospective evaluation by Knoebl et al in the same issue of Blood reporting the effects of emicizumab for bleeding control in 12 patients with acquired hemophilia A, a rarely encountered autoimmune bleeding disease requiring prompt diagnosis and urgent treatment. Emicizumab, a recombinant, humanized, bispecific monoclonal antibody that mimics the function of activated FVIII, is approved for prophylaxis, with and without inhibitors, in patients with congenital hemophilia A.